首页> 美国卫生研究院文献>Annals of Oncology >Safety efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab a PD-1 antibody in phase Ib/II clinical trial NCT02915432

【2h】

Safety efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab a PD-1 antibody in phase Ib/II clinical trial NCT02915432

机译：在Ib / II期临床试验NCT02915432中PD-1抗体托利帕单抗治疗的化学难治性胃癌的整体生存获益的生物标志物的安全性有效性和肿瘤突变负担

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundHigh tumor mutational burden (TMB-H) is correlated with enhanced objective response rate (ORR) and progression-free survival (PFS) for certain cancers receiving immunotherapy. This study aimed to investigate the safety and efficacy of toripalimab, a humanized programmed death-1 (PD-1) antibody, in advanced gastric cancer (AGC), and the predictive survival benefit of TMB and PD-L1.

机译：背景高肿瘤突变负担（TMB-H）与某些接受免疫治疗的癌症的客观应答率（ORR）和无进展生存期（PFS）增强相关。这项研究旨在调查托里帕单抗（一种人源化程序性死亡1（PD-1）抗体）在晚期胃癌（AGC）中的安全性和有效性，以及TMB和PD-L1的预测生存获益。

著录项

期刊名称 Annals of Oncology
作者
F Wang; X L Wei; F H Wang; N Xu; L Shen; G H Dai; X L Yuan; Y Chen; S J Yang; J H Shi; X C Hu; X Y Lin; Q Y Zhang; J F Feng; Y Ba; Y P Liu; W Li; Y Q Shu; Y Jiang; Q Li; J W Wang; H Wu; H Feng; S Yao; R H Xu;
展开▼
作者单位

展开▼
年(卷),期 -1(30),9
年度 -1
页码 1479–1486
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
gastric cancer immunotherapy programmed death ligand-1 tumor mutational burden;

机译：胃癌;免疫疗法;程序性死亡配体-1;肿瘤突变负担;
入库时间 2022-08-21 10:50:30

相似文献

外文文献
中文文献
专利

1. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02) [J] . Wang Feng-Hua, Wei Xiao-Li, Feng Jifeng, Journal of Clinical Oncology . 2021,第7期

机译：以前治疗的复发性或转移性鼻咽癌患者的菌丝，安全性和相关生物标志物：II期临床试验（Polaris-02）
2. Tumor mutational burden as a new biomarker for PD-1 antibody treatment in gastric cancer [J] . Gunnar Folprecht Chinese journal of cancer . 2019,第1期

机译：肿瘤突变负担作为胃癌PD-1抗体治疗的新生物标志物
3. Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial [J] . Lu Ming, Zhang Panpan, Zhang Yanqiao, Clinical cancer research: an official journal of the American Association for Cancer Research . 2020,第10期

机译：反荷尼替金属患者的疗效，安全和生物标志物在复发性或转移性神经内分泌肿瘤患者中：多重中心IB试验
4. Clinical studies of SP1049C, a polymer based anthracycline effective against drug resistant tumors. Results of phase II trial and pivotal phase Ⅲ program in upper gastrointestinal cancer indications [C] . Valery Alakhov Controlled Release Society Annual Meeting and Exposition . 2007

机译：SP1049C的临床研究，一种基于聚合物的蒽环类药物可有效抵抗耐药性肿瘤。上消化道癌适应症的II期试验和关键性III期试验结果
5. Tumor mutational burden as a new biomarker for PD-1 antibody treatment in gastric cancer [O] . Gunnar Folprecht 2019

机译：肿瘤突变负担作为胃癌PD-1抗体治疗的新生物标志物
6. Safety and Efficacy of PD-1 Antibody SHR-1210 Combined with Concurrent Chemoradiotherapy to Treat Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase Ib Clinical Trial [O] . Q. Pang, W. Zhang, J. Zhao, 2020

机译：PD-1抗体SHR-1210的安全性和功效联合同时的化疗治疗局部晚期食管鳞状细胞癌：IA相临床试验

Safety efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab a PD-1 antibody in phase Ib/II clinical trial NCT02915432

摘要

著录项

相似文献

相关主题

期刊订阅